Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium

Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium

Purple Biotech's abstract for its lead tri-specific antibody, IM1240, has been accepted for an oral presentation at the upcoming 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today.

Crude Oil Moves Higher; US Factory Orders Rise In July

U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.

Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings

U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.

Why Is Purple Biotech Stock Gaining Wednesday?

Purple Biotech (PPBT) stock surged premarket after receiving a USPTO patent allowance for its CAPTN-3 tri-specific antibody platform.

Purple Biotech shares are trading higher after the company announced the U.S. PTO issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use.